Advertisement

Der Gastroenterologe

, Volume 3, Issue 4, pp 303–308 | Cite as

Reflux in der Schwangerschaft

Differenzialdiagnosen und gesicherte Therapien
  • S. Fill MalfertheinerEmail author
  • S.-D. Costa
Schwerpunkt
  • 108 Downloads

Zusammenfassung

Ein gastroösophagealer Reflux tritt in der Schwangerschaft sehr häufig auf. Dabei ist es unklar, wie oft es sich um eine schwangerschaftsimmanente Erscheinung handelt und wie oft um eine schwangerschaftsunabhängige gastroösophageale Refluxkrankheit (GERD). Inadäquat oder nicht behandelt können Reflux und GERD die Lebensqualität der Schwangeren erheblich beeinträchtigen. Hauptursache für einen Reflux in der Schwangerschaft ist ein Abfall des unteren Ösophagussphinktertonus, hervorgerufen durch schwangerschaftsbedingte Veränderungen der Sexualhormone. Symptomatische GERD in der Schwangerschaft sollte den Richtlinien eines europäischen Konsensusmeeting (2003) zufolge entsprechend einem Step-up-Algorithmus behandelt werden, beginnend mit spezifischen Lifestyle-Änderungen. Medikamente der ersten Wahl sind Antazida. Wenn die Symptome persistieren, stehen Histamin-2-Rezeptorantagonisten zur Verfügung. Protonenpumpeninhibitoren werden laut den europäischen Richtlinien in der Schwangerschaft nicht empfohlen.

Schlüsselwörter

Gastroösophageale Refluxkrankheit GERD Sodbrennen Schwangerschaft GERD-Therapie GERD-Therapie in der Schwangerschaft 

Reflux in pregnancy

Secure and differential treatment

Abstract

Gastroesophageal reflux occurs often in pregnancy and is usually interpreted as being intrinsically related to pregnancy and thus not a “real disease.” If the reflux symptoms are inadequately cared for, then gastroesophageal reflux disease (GERD) can have a severe affect on the quality of life of the pregnant woman. The main cause of reflux during pregnancy is a decrease in the lower esophageal sphincter tonus due to hormone level changes brought on by the pregnancy. Symptomatic GERD during pregnancy should be treated according to the step-up algorithm put forth by the European consensus meeting guidelines in 2003, starting with specific lifestyle changes. Antacids are the medication of first choice. Should the symptoms persist, then histamine-2 receptor antagonists can be given. Proton pump inhibitors are not recommended for pregnant women by the consensus meeting guidelines.

Keywords

Gastroesophageal reflux disease GERD Heartburn Pregnancy GERD-treatment GERD-treatment during pregnancy 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Al-Amri SM (2002) Twenty-four hour ph monitoring during pregnancy and at postpartum. Eur J Obstet Gynecol Reprod Biol 10;102: 127–130Google Scholar
  2. 2.
    Alvarez-Sanches, Rey, Achem, Diaz Rubio M (1999) Does progesterone fluctuation across the menstrual cycle predispose to gastrooesophageal reflux? Am J Gastroenterol 94: 1468–1471Google Scholar
  3. 3.
    Baron TH, Richter JE (1992) Gastroesophageal reflux disease in pregnancy. Gastroenterol Clin North Am 21: 77–791Google Scholar
  4. 4.
    Briggs GG, Freeman RY, Yaffe SJ (2002) Drugs in pregnancy and lactation: A reference guides to fetal and neonatal risk. Williamand Wilkins, Baltimore, USAGoogle Scholar
  5. 5.
    Brunner G, Meyerr H, Athmann C (1998) Omeprazole for peptic ulcer disease in pregnancy. Digestion 59: 651–654PubMedCrossRefGoogle Scholar
  6. 6.
    Broussard SN, Richter JE (1998) Treating gastro-esophageal reflux disease during pregnancy and lactation. What are the saftest therapie options? Drug Saf 4: 325–327CrossRefGoogle Scholar
  7. 7.
    Capell MS (1998) The safety and efficacy of gastrointestinal endoscopy during pregnancy. Gastroenterol Clin North Am 27: 37–71CrossRefGoogle Scholar
  8. 8.
    Ching C, Lam S (1994) Antacids: indications and limitations. Drugs 47: 305–317PubMedCrossRefGoogle Scholar
  9. 9.
    Diav-Citrin O, Arnon J, Shechtman S et al. (2005) The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther 21: 269–275PubMedCrossRefGoogle Scholar
  10. 10.
    Fill S, Malfertheiner M, Costa SD et al. (2007) Handling of the gastroesophageal reflux disease (GERD) during pregnancy – a review. Z Geburtshilfe Neonatol 211: 215–223PubMedCrossRefGoogle Scholar
  11. 11.
    Finkelstein W, Isselbacker KJ (1978) Cimetidine. N Engl J Med 229: 992–996Google Scholar
  12. 12.
    Larson JD, Patatanian E, Miner PB et al. (1997) Double-blind, placebo-controlled study af ranitidine for gastroesophageal reflux symptoms during pregnancy. Obstet Gynecol 90: 83–87PubMedCrossRefGoogle Scholar
  13. 13.
    Leite LP, Johnston BT, Garrett J et al. (1997) Nonspecific esophageal motility disorder is primarily ineffective esophageal motility: is it associated with abnormal recumbent acid exposure? Dig Dis Sci 42: 1859–1865PubMedCrossRefGoogle Scholar
  14. 14.
    Lind JF, Smith AM, McKiver DK et al. (1968) Heartburn in pregnancy – a manometry study. CMAJ 98: 571–574Google Scholar
  15. 15.
    Magpie trial collaboration group (2002) Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? A randomised trial. Lancet 359: 1877–1890CrossRefGoogle Scholar
  16. 16.
    Marrero JM, Goggin PM, Caestecker JS de (1992) Pearce, Maxwell. Determinants of pregnancy heartburn. Br J Obstet Gynaecol 99: 731–734PubMedGoogle Scholar
  17. 17.
    Morton DM (1987) Pharmacology and toxicity of nizatidine. Scand J Gastroenterol 22 (136): 1–8CrossRefGoogle Scholar
  18. 18.
    Nagler R, Spiro HM (1961) Heartburn in the late pregnancy: manometric studies of esophageal motor function. J Clin Invest 40: 945–970CrossRefGoogle Scholar
  19. 19.
    Neubauer BL, Goode RL, Bert KK et al. (1990) Endocrine affects af a new histamine H2 receptor antagonist, nizatidine in the male rat. Toxicol Appl Pharmacol 102: 219–232PubMedCrossRefGoogle Scholar
  20. 20.
    Nikfar S, Abdollahi M, Moretti ME et al. (2002) Use of proton pump inhibitors during pregnancy and rates of major malformations. A meta-analysis. Dig Dis Sci 47: 1526–1529PubMedCrossRefGoogle Scholar
  21. 21.
    Astra-Zeneca (2004) Prilosec (product information). Wilmington/DE, USAGoogle Scholar
  22. 22.
    Richter JE (2005) Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther 22(9): 749–757PubMedCrossRefGoogle Scholar
  23. 23.
    Rey E, Rodriguez-Artalejo F, Herraiz MA et al. (2007) Gastroesophageal reflux symptoms during and after pregnancy: a longitudinal study. Am J Gastroenterol 102: 2395–2400PubMedCrossRefGoogle Scholar
  24. 24.
    Ruigomez A, Rodriguez LAG, Cattaruzzi C et al. (1999) Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 150: 476–481PubMedGoogle Scholar
  25. 25.
    Savarino V, Giasti M, Scalabrini P et al. (1988) Famotidine has no significant affect on gonadal function in men. Gastroenterol Clin Biol 12: 19–22PubMedGoogle Scholar
  26. 26.
    Schardein JL, Furuhashi T, Ooshima Y (1990) Reproductive and developmental toxicity studies of lansoprazole (AG-1749) in rats and rabbits. Jpn Pharmacol Ther 18: 119–129Google Scholar
  27. 27.
    Torbey CF, Richter JE (1995) Esophageal disorders during pregnancy. Pract Gastroenterol 19: 22–36Google Scholar
  28. 28.
    Tytgat GN, Heading RC, Muller-Lissner S et al. (2003) Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting. Aliment Pharmacol Ther 18: 291–301PubMedCrossRefGoogle Scholar
  29. 29.
    Van Thiel DH, Wald A (1981) Evidence refuting a role for increased abdominal pressure in the pathogenesis of the heartburn associated with pregnancy. Am J Obstet Gynecol 140: 420–422Google Scholar
  30. 30.
    Witten FP, King TM, Blake O (1981) The effects of chronic gastrointestinal medication on the fetus and neonate. Obstet Gynecol 58: 79S–84SGoogle Scholar

Copyright information

© Springer Medizin Verlag 2008

Authors and Affiliations

  1. 1.Universitätsfrauenklinik Otto-von-Guericke-UniversitätMagdeburgDeutschland

Personalised recommendations